reports
- Marc Zwartsenburg
- CEFA
ING Benelux Favourites/Weekly performance and valuation update
We update the performance of our ING Benelux Favourites list as well as all valuation and ranking tables for our coverage universe. Performance on the front page is dated from the 28 January 2026, while historical performance is included on the second page. The methodology for our favourites selection is based on a bottom-up approach with a focus on absolute performance with clear near-term triggers. It is a rolling list, ie, stocks can enter/exit whenever we think opportune. The ING Benelux Fav...
- Arancha Pineiro
AHOLD DELHAIZE: RDOS. 4T'25 (ANÁLISIS BANCO SABADELL)
Rdos. 4T'25 vs 4T'24: Ventas: 23.490 M euros (+0,9% vs +0,8% BS(e) y +0,4% consenso); EBIT: 994,0 M euros (+3,8% vs -4,3% BS(e) y -4,2% consenso); BDI: 577,0 M euros (+51,8% vs +55,3% BS(e) y +57,4% consenso); Rdos. 2025 vs 2024: Ventas: 92.352 M euros (+3,4% vs +3,3% BS(e) y +3,2% consenso); EBIT: 3.734 M euros (+3,5% vs +1,4% BS(e) y +1,4% consenso); BDI: 2.263 M euros (+28,3% vs +29,0% BS(e) y +29,5% consenso).
- Research Department
INFORME DIARIO 11 FEBRERO + RDOS. ESPAÑA Y EUROPA 4T’25. IDEAS DESTACA...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ENDESA, INDRA, SANTANDER, SECTOR SEGUROS, TELEFÓNICA. EUROPA: AHOLD DELHAIZE, BAYER. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 4T’25 que se publicarán en España y Europa en los próximos días. El Ibex mantiene los 18.100 puntos Ligeras caídas en los mercados en una jornada de transición a la espera de l...
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summi...
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 Daix (France), New York (United States), February 4, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. The conference is being held February 11-12, 2026 at the Lotte New Yor...
Inventiva présentera au Guggenheim Emerging Outlook : Biotech Summit 2...
Inventiva présentera au Guggenheim Emerging Outlook : Biotech Summit 2026 Daix (France), New York (États-Unis), le 4 février 2026 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que son Directeur général, Andrew Obenshain, a été invité à participer à un « fireside chat » lors du prochain Guggenheim Emerging Outlook: Biotech Summit 2026. La conférence se tiendra le...
- ING Helpdesk
Benelux Morning Notes
Aalberts: Preview: Another quarter in no man's land? / Ahold Delhaize: Confirms the acquisition of Delfood / AGEAS: China – state to inject capital into insurers / AkzoNobel: Tepid 4Q25 results and FY26 outlook / D'Ieteren: Belgian car registrations down 19%, 65% of 2019 level, VW down only 5% / Xior Student Housing: Sound organic trends continue, two-year guidance revealed
- David Vagman
- CFA
- Dirk Verbiesen
- Francesca Ferragina
- Jason Kalamboussis
- Marc Hesselink
- CFA
- Marc Zwartsenburg
- CEFA
- Maxime Stranart
- Michiel Vereycken
- Quirijn Mulder
- Reg Watson
- CFA
- Thymen Rundberg
- Tijs Hollestelle
ING Benelux Favourites/Aedifica, Ageas, ASM International, Basic-Fit, ...
We refresh our ING Benelux Favourites list. We apply a fundamental bottom up approach in which we select stocks which provide the best upside within our Benelux coverage universe and these stocks need clear catalysts. Additions/deletions: We add the following names to the ING Benelux Favourites list: Ageas: Ageas has done multiple deals; its most recent purchase of the 25% stake BNP Paribas had in its Belgian ops, is an accretive deal and we believe makes the Belgian operations ready for a pot...
- Jason Kalamboussis
Ageas/Shaking shackles, coming together/BUY
Moving away from dependence on Asian earnings (now c.30%), while carefully managing its M&A path, we believe AGEAS is well positioned to see an earnings acceleration in the coming years. China upstreams are coming through, while the share price of its Chinese partner CTIH has doubled in 12 months. BNP PARIBAS has increased its stake in the Group (from c.15% to c.23%) at the same time moving out of the Belgian entity AG, and the Belgian government is looking at options to increase its 6.3% stake....
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvre...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resou...
Bilan semestriel du contrat de liquidité de la société Inventiva concl...
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Daix (France), New York City (New York, Etats-Unis), le 26 janvier 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique ("MASH"), annonce aujourd’hui le bilan semestriel de son contrat de liquidité conclu avec Kepler Cheuvreux. Au titre du contrat de liquidité portant sur les actions de la Société confié à Kepler Cheuvreux,...
- Ahmed Ben Salem
- Emira Sagaama
- Oddo Sustainability Team
- Ahmed Ben Salem
- Emira Sagaama
- Oddo Sustainability Team
- Cor Kluis
- Carole Braudeau
- Carole Braudeau
- Guy Sips
- Hilde Van Boxstael
- Michiel Declercq
- Thomas Couvreur
- Wim Lewi
- ING Helpdesk
Ageas announces Net Operating Result guidance update
Ageas announces Net Operating Result guidance update Ageas announces Net Operating Result guidance update Today China Taiping Insurance Holding (CTIH) published a pre-announcement on its full year 2025 results related to the announcement made by The Chinese Ministry of Finance and the State Administration of Taxation concerning the corporate income tax treatment in relation to the transition to IFRS17/9. This new regulation requires an update to the deferred taxes reported for the financial years 2023 and 2024. This update will result in a positive one-off impact on the deferred taxe...
Ageas annonce une mise à jour de la guidance du Résultat Opérationnel ...
Ageas annonce une mise à jour de la guidance du Résultat Opérationnel Net Ageas annonce une mise à jour de la guidance du Résultat Opérationnel Net Aujourd’hui, China Taiping Insurance Holding (CTIH) a publié une préannonce concernant ses résultats pour l’exercice 2025, liée à l’annonce faite par le Ministère chinois des Finances et l’Administration d’État de la Fiscalité concernant le traitement de l’impôt sur les sociétés dans le cadre de la transition vers les normes IFRS17/9. Cette nouvelle réglementation nécessite une mise à jour des impôts différés déclarés pour les exercices 2023 et...
Ageas kondigt bijstelling aan van het verwachte Netto Operationeel Res...
Ageas kondigt bijstelling aan van het verwachte Netto Operationeel Resultaat Ageas kondigt bijstelling aan van het verwachte Netto Operationeel Resultaat Vandaag publiceerde China Taiping Insurance Holding (CTIH) een kennisgeving voorafgaand aan haar resultaten over het volledige jaar 2025 gelinkt aan de aankondiging van het Chinese Ministerie van Financiën en de Staatsadministratie van Belastingen over de behandeling van de vennootschapsbelasting in verband met de overgang naar IFRS17/9. Deze nieuwe regelgeving vereist een bijstelling van de uitgestelde belastingen die werd gerapporteerd...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.